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Letters to the EditorReply to the Editor:
We thank Takagi and colleagues for
their interest in our work and their
update, which completes and supports
our results.1 Among the RAPCO
reports published during the years
covered by our research (January
1966–March 2009), we chose to include
the study by Buxton and colleagues2
published in 2003 and exclude the report
by Hayward and collaborators3 pub-
lished in 2007 because the latter study
included patients undergoing serial
angiography and, more importantly,
because in that analysis saphenous
vein was grafted to second-, third- and
fourth-order coronary vessels, thus
affecting overall patency rate.
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WHAT IS THE PROBLEM?
To the Editor:
Congratulations to Dasi and coau-
thors1 for their valuable study on Fon-
tan hemodynamics. Eleven patients
underwent lateral tunnel procedures,
and 11 underwent total cavopulmonary
connection through an extracardiac
Fontan operation. We have previously
proposed that contractility and ventric-
ular stress tests should be reevaluatedThe Journalwith different measurement methods,2
although our opinions do not coincide
with those of some other authors.3
We think that there should be a consen-
sus regarding methods used to measure
contractility and ventricular stress with
respect to Fontan hemodynamics.
Consideration of our opinions on this
issue by Dasi and coauthors1 would
be appreciated and would help us in so-
lution of this enigma.
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We thank Kestelli and colleagues for
their letter on this important topic.
Fontan failure1,2—defined here as poor
prognosis after the Fontan operation—
may occur at either an early or a late
stage. Most late failures are in older pa-
tients with the classic atriopulmonary
connection, with problems including ar-
rhythmias, thromboembolism, heart
failure, and pulmonary venous block-
age. Early failures include arteriovenous
malformations and protein-losing enter-
opathy, occurring mostly in patients
with a total cavopulmonary connection.
Heart failure appears eventually if no
other failure mode manifests. Theseof Thoracic and Cardiovascular Surgervarying failure modes clearly show
that the problem is complex, multifacto-
rial, and still unfolding as more and
more patients who underwent total cav-
opulmonary connection in the mid
1990s are now reaching adulthood.
Eventhoughall thesepatientshaveasin-
gle-ventricle physiology that is inher-
ently preload limited with increased
afterload,3 it is not yet clear whether pre-
load limitation is the only cause. There
are other independent factors (quality
of connection, afterload, underlying
congenital defect).
The specific modes of failure for
a given patient depend on the severity
of the underlying congenital heart de-
fect, efficacy of the palliative approach
chosen, and the health and composi-
tion of the interacting organ system, in-
cluding the lungs and abdominal
viscera. We have just begun a National
Institutes of Health–funded predictive
study to help determine the specific
criteria for efficient management of
these patients. For instance, patients
in whom the hepatic flow return is
biased toward a single lung may have
arteriovenous malformations develop.
Those with a highly energy-
dissipating total cavopulmonary con-
nection may have decreased preload,
poor exercise tolerance, or high central
venous pressure, leading to protein-
losing enteropathy or heart failure.
There is no predictive model currently
available that can determine the precise
contributors to and mechanisms of fail-
ure in a given patient, even when all
hemodynamic information is available.
We hope that our ongoing research
will provide more definite answers to
these questions in the coming years.
In the final analysis, for many pa-
tients with Fontan circulation, survival
into the 4th or 5th decade may require
innovative solutions, such as that pro-
posed by Kestelli and associates.4
There are many concerns regarding
the proposed solution, however, which
may be trading one problem for many
others. The proposed solution is en-
ergy neutral (energy available to drive
the circulation is still the same,y c Volume 139, Number 6 1673
Letters to the Editoralthough it is used differently) but re-
quires the single ventricle to pump sig-
nificantly more volume to maintain the
same cardiac output, thus decreasing
net cardiac output. The theoretic gains
in pulsatility and pulmonary vascular
resistance must be balanced by the
risks of low cardiac output, ventricu-
lotomy, and thrombosis related to the
valves in the pulmonary circuit. Nev-
ertheless, these are just theoretic pre-
dictions, and detailed in vitro and in
vivo studies are necessary to assess
the true efficacy of this and other novel
solutions. Venous and mechanical
supports that provide an additional en-
ergy source are being studied through
progressing animal models and may
offer the best hope for some patients.5
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ANTIBODY
ANTI-CYTOKERATIN CAM 5.2
IS SPECIFIC FOR
INTRACELLULAR
CYTOKERATIN 8, NOT
CYTOKERATIN 18
To the Editor:
We read with great interest the con-
tribution by Grotenhuis and colleagues
regarding the article entitled ‘‘The sen-
tinel node concept in adenocarcinomas
of the distal esophagus and gastro-
esophageal junction.’’1 However, the
authors might have inadvertently an-
notated the NCL 5D3 clone to be the
source of the murine monoclonal anti-
body CAM 5.2 and unsuitably sug-
gested CAM 5.2 to be specific to
cytokeratins 8 and 18 in their experi-
ment as well.1
We would like to comment and clar-
ify that anti-cytokeratin CAM 5.2 was
different from cytokeratin 8/18 mono-
clonal antibody. Monoclonal antibody
to cytokeratin 8/18, instead of anti-cyto-
keratin CAM 5.2, was originally devel-
oped and manufactured by Novocastra
Laboratories Ltd (Newcastle Upton
Tyne, United Kingdom) using the brand
Novocastra. The company grew and in
2003 was integrated into Vision Bio-
Systems (Wetzlar, Germany). Today,
Novocastra has become an important
part of the overall histology range of Le-
ica Microsystems’ Biosystems Division
through this definitive merger.
Therefore, monoclonal antibody to
cytokeratin 8/18 is produced by Leica
Microsystems’ Biosystems Division,
which is derived from the 5D3 clone.Cardiovascular Surgery c June 2010This clone reacts with human
cytokeratin-intermediate filament pro-
teins at 52.5 and 45 kd, which are
identified as cytokeratins 8 and 18,
respectively.2 On the other hand,
anti-cytokeratin CAM 5.2 reagent is
produced by Becton Dickinson Biosci-
ences (Franklin Lakes, NJ) and is de-
rived from the clone CAM 5.2. This
clone reacts with human cytokeratin-
intermediate filament proteins at 48
and 52 kd, which are identified as cyto-
keratins 7 and 8, respectively.3 In addi-
tion, Becton Dickinson Biosciences
(1977) revised the data sheet for anti-
cytokeratin CAM 5.2 to have a primary
reactivity with cytokeratin 8 and, in
addition, a weaker but distinct reactiv-
ity with cytokeratin 7. The data sheet
also shows that there is no reactivity
with cytokeratins 18 or 19. As a result,
CAM 5.2 is not synonymous with
cytokeratins 8 and 18.4 We concluded
that the murine monoclonal antibody
CAM 5.2 will not be specific for
intracellular cytokeratins 8 and 18.
Wen-Chang Cheng, MDa,*
Jeng-Dong Hsu, DDS, MSb,c,*
Chung-Chin Yao, MD, PhDc,d,*
Chih-Ping Han, MD, PhDe
aDepartment of Diving Medicine
Hyperbaric Oxygen Therapy &
Wound Care Center
bDepartment of Pathology
cSchool of Medicine
dDepartment of Surgery
eInstitute of Medicine
Department of Obstetrics and
Gynecology
Clinical Trial Center
Chung-Shan Medical University
Hospital &
Chung-Shan Medical University
Taichung, Taiwan, ROC
*These authors contributed equallyReferences
1. Grotenhuis BA, Wijnhoven BP, van Marion R, van
Dekken H, Hop WC, Tilanus HW, et al. The sentinel
node concept in adenocarcinomas of the distal
esophagus and gastroesophageal junction. J Thorac
Cardiovasc Surg. 2009;138:608-12.
2. Leica Microsystems. Novocastra lyophilized mouse
monoclonal antibody cytokeratin (8/18). Product
code NCL-5D3. 2008. Available at: http://
